Final trial data from ELI-002 cancer immunotherapy vaccine reinforce promising results
MD Anderson Research Highlight August 12, 2025
In initial results from the AMPLIFY-201 trial, co-led by , an immunotherapy vaccine targeting the lymph nodes showed potential in delaying relapse of KRAS-mutated pancreatic and colorectal cancers for patients who had previously undergone surgery. Long-term final follow-up data of this vaccine, ELI-002 2P, now shows that 17 of 25 patients (68%) had robust T cell responses, which were associated with increased survival. At 24 months, the median recurrence-free survival had not yet been reached for the higher response group ¨C including all of the patients at the highest two dose levels ¨C with 75% of them still relapse-free, compared to three months for patients who were not high responders. These data prompted the initiation of a Phase II trial that is currently ongoing and includes a new formulation of the vaccine (ELI-002 7P) targeting additional KRAS mutations. Learn more in .
These final data continue to show strong, durable immune responses, which is encouraging for patients at high risk of relapse and is a promising step forward in addressing an unmet need in cancer care.